Editorial comment
At The Children's Hospital of Philadelphia we have had an extensive experience with this rare tumour, as oncology referrals are received widely in this centre. As a result we have identified several points that are worth reiterating. The first is that this is a rare tumour that is complex in management and unlike any other malignancy seen in children. Accordingly, this is a malignancy that cannot be managed by a simple 'cookbook' approach and should be managed in a centre of excellence that has abundant experience with this tumour.
This tumour responds to all three modes of treatment, i.e., chemotherapy, radiotherapy and surgery. Indeed, there is a feeling among many that multimodal therapy is required to cure the patients. The exact balance and appropriateness in a given child of these three elements continue to be debated, and I am at variance with some recommendations in this review. The first point to emphasise is that children who have this tumour might have a mass that remains after chemotherapy but that does not reflect the cancer burden. Often the stroma involutes far more slowly than does the cancer. Accordingly, the staging of this tumour should always be with histology as well as imaging. Indeed, imaging alone is simply not sufficient.
Another important point that we have learned when we are striving to achieve a cure of this tumour is to not irradiate residual mass disease, but rather ensure that the patient has no gross evidence of disease (NED) before considering any radiotherapy. An irradiated tumour simply has uninterpretable pathology, as the pathologist cannot determine whether a cell that is visible on biopsy is moving towards senescence or viability. We always strive to create a patient with NED by either chemotherapy or chemotherapy plus surgery before considering radiotherapy. An important point is that it has been now recognised that chemotherapy and radiotherapy can satisfactorily treat microscopic residual disease. As a result, exonerative surgery for this unencapsulated tumour, in an effort to establish a wide field of normal tissue around the cancer, is rarely necessary. If the organ of origin of the tumour is removed and there is microscopic residual disease, usually that can be dealt with by radiotherapy and further chemotherapy.
The result of all of these changes over the last 30 years is that we have clearly improved the long-term prognosis for many of these children, although much remains to be determined. This present review is worthy of careful study. 
